Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

• Published in: Nature communications Vol. 12; no. 1; pp. 2607 - 13
• Main Authors: Wang, Feng, Morita, Kiyomi, DiNardo, Courtney D., Furudate, Ken, Tanaka, Tomoyuki, Yan, Yuanqing, Patel, Keyur P., MacBeth, Kyle J., Wu, Bin, Liu, Guowen, Frattini, Mark, Matthews, Jairo A., Little, Latasha D., Gumbs, Curtis, Song, Xingzhi, Zhang, Jianhua, Thompson, Erika J., Kadia, Tapan M., Garcia-Manero, Guillermo, Jabbour, Elias, Ravandi, Farhad, Bhalla, Kapil N., Konopleva, Marina, Kantarjian, Hagop M., Andrew Futreal, P., Takahashi, Koichi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.05.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 45/23; 45/61; 45/91; 631/67; 631/67/1990/283; 631/67/1990/283/1897; 631/67/68; 631/67/69; Acute myeloid leukemia; Allosteric properties; Cytosine; Deoxyribonucleic acid; DNA; DNA methylation; DNA sequencing; Drug resistance; Genomic analysis; Homology; Humanities and Social Sciences; IDH gene; Inhibitors; Leukemia; multidisciplinary; Mutants; Mutation; Myeloid leukemia; Runx1 protein; Science; Science (multidisciplinary)

Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of acute myeloid leukemia (AML) patients with the mutations. However, primary resistance and acquired resistance to the drugs are maj...